Latest Morning Briefing Stories
A rural hospital chain goes bust while a big urban one reports higher profits. In other hospital industry news, the government won’t penalize hospitals that donate or sell unpaid bills to charities that pay off the debts.
Despite the imminent expiration of current aid, a quick path to another round of coronavirus stimulus gets tougher as a number of Republican senators object to several of the provisions in their party’s proposal.
California officials say the ban is necessary to prevent drug companies from thwarting competition and maintaining higher prices. In other news from the state: Legislators say they may offer extra jobless benefits if the federal government doesn’t act in time; and how California’s pandemic fight compares with New York’s.
As Senate Majority Leader Mitch McConnell unveiled $1 trillion stimulus package, White House officials turned negotiating efforts to House Democrats.
While signing executive orders aimed at lowering prescription drug prices, President Donald Trump said he would meet today with industry leaders to discuss the measures. But no pharma executives opted to join. The executive orders have not yet been made public.
Even as Senate Republicans are poised to release their $1 trillion stimulus package hammered out with the White House, top Trump administration officials suggest that more narrow legislation may be needed as benefits are set to expire.
President Donald Trump signed four executive orders Friday aimed at reducing the costs of medications like insulin that have risen to unaffordable levels for many Americans.
Moderna loses a patent court case that could delay its COVID-19 vaccine while a China-owned pharmaceutical group and Imperial College London announce progress on their versions. Meanwhile, the Trump administration’s $2 billion “Operation Warp Speed” deal with Pfizer raises concerns about vaccine prices.
Remaining differences between the White House and Senate Republicans forced leadership to hold off on introducing their proposed $1 trillion coronavirus relief bill.
Who gets rich off of the race for a coronavirus vaccine–even if they don’t finish the race? And news about remdesivir shortages.
The Department of Health and Human Services quietly announced the news Monday. Other health industry news comes from Beaumont Health, Memorial Hermann, CHS, Quorum Health, Hims & Hers, HCA and other groups.
The Trump administration announced its largest purchase yet as the federal government commits huge sums to another drugmaker to secure access to its potential COVID-19 vaccine.
After days of negotiation, Senate Republican leaders announce that they reached tentative agreement with the Trump administration on key measures, including stimulus checks, virus testing and school funding. Contentious issues remain though, and Democrats must still be brought on board.
With record numbers out of work, fewer payroll taxes are coming in to fund Medicare — at the same time more people are enrolling and Congress dips into Medicare’s reserves to help fund COVID-19 relief efforts.
Back-and-forth negotiations Tuesday between the White House and Senate Republicans yielded little agreement — but a lot of ire — over the scope and cost of the next pandemic funding legislation.
Modern Healthcare investigates how CMS’ recent proposal “could have wide-ranging implications for the 340B program.”
Stat reports on a potential financial conflict of interest for two House lawmakers during a hearing on vaccine development, as well as the stepped-up lobbying by pharmaceutical companies.
The digital campaign asks constituents to call their senators and tell them to “stop stalling” on the bill.
While common ground with Democrats is still far off, disagreements remain between the Trump administration and congressional Republican leaders after a White House meeting. At issue is money for virus testing, schools and payroll taxes while a surprise billing measure appears to be off the table.
Also in the news: why a COVID test is like a pregnancy test; scientists discover six different types of the disease; and the question of who should pay the tab for testing.